BioRestorative shares multi-year phase 2 data as BRTX-100 moves toward phase 3

BioRestorative Therapies (NASDAQ:BRTX) announced significant clinical progress in its lead cell therapy program, BRTX-100, reporting expanded blinded Phase 2 data that demonstrates long-term efficacy for patients suffering from chronic lumbar disc disease (cLDD).

The results, which track patient outcomes through 52 and 104 weeks, suggest that the investigational therapy provides sustained relief and functional recovery in a patient population with few non-surgical options.

At the 52-week mark, 52% of evaluable patients (n=25) achieved a primary composite endpoint of at least a 50% improvement in both the Visual Analog Scale (VAS) for pain and the Oswestry Disability Index (ODI) for function.

This dual-improvement metric is considered a high bar for clinical success in degenerative disc trials.

The expanded data set highlighted that mean improvements in pain and disability were not only significant at one year but were sustained through the 104-week follow-up.

Improvements were consistent across multiple validated clinical measures, including the Roland-Morris Disability Questionnaire (RMDQ) and the Functional Rating Index (FRI).

Importantly, the safety profile remains robust, with no dose-limiting toxicities or significant treatment-related adverse events observed to date.

BRTX-100, which utilizes a patient’s own (autologous) hypoxic-cultured mesenchymal stem cells, currently holds FDA Fast Track designation, a status intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.

Following a recent meeting with the U.S. Food and Drug Administration (FDA), BioRestorative confirmed that it has reached an alignment on the design and requirements for a Phase 3 registrational study.

The company has initiated Phase 3-enabling activities, which include manufacturing scale-up and site selection protocols.

BioRestorative aims to submit an Investigational New Drug (IND) application for the Phase 3 trial later in 2026.

This transition to late-stage clinical development marks a pivotal shift for the company as it seeks to move its musculoskeletal platform toward commercial viability.